New member of CF's colorectal cancer team unveiled at General Council meeting in Lisbon
Prof. Bill Heald joins CF's colorectal cancer faculty in Lisbon.
Friday, July 12th, saw the year's second meeting of the Champalimaud Foundation’s General Council in Lisbon. As usual, this meeting gave the Council, chaired by Daniel Proença de Carvalho, the opportunity to discuss and appraise the Foundation’s ongoing work in the fields of cancer and neuroscience. This first meeting of the year provided the opportunity for the presentation of Professor Bill Heald, one of the world’s foremost authorities on colorectal cancer surgery.
Foundation President, Leonor Beleza, announced that Prof. Heald has agreed to join the CF’s colorectal cancer team, with an emphasis on providing the most effective treatment while maintaining the highest possible levels of quality of life for the patient. In particular, the CF’s colorectal cancer team promotes active surveillance strategies which reduce the need for invasive procedures where possible. By monitoring the disease in this way, the patient’s quality of life is maximised and the need for invasive treatment is reduced. However, the CF’s highly trained colorectal surgeons are ready to intervene immediately if the cancer takes on more aggressive characteristics.
Professor Bill Heald brings his vast experience and expertise in this field to the Champalimaud Foundation. He is Director of Surgery at the UK’s Pelican Cancer Foundation and his main interest for the past 30 years has been the research and development of the Total MesorectalExcision (TME) technique for rectal cancer. He is a former Vice-President of the Council at the Royal College of Surgeons of England. He is past-President of the Section of Coloproctology at the Royal Society of Medicine and of the Association of Coloproctology.
Prof. Heald has performed over 500 operations in more than 50 countries around the world.